Skip to main content
Cancer Biology & Medicine logoLink to Cancer Biology & Medicine
. 2020 May 15;17(2):513. doi: 10.20892/j.issn.2095-3941.2020.0029

Erratum to Prevalence and clinical significance of pathogenic germline BRCA1/2 mutations in Chinese non-small cell lung cancer patients

Xingsheng Hu 1, Dongyong Yang 2, Yalun Li 3, Li Li 4, Yan Wang 5, Peng Chen 6, Song Xu 7, Xingxiang Pu 8, Wei Zhu 9, Pengbo Deng 10, Junyi Ye 11, Hanhan Zhang 11, Analyn Lizaso 11, Hao Liu 11, Xinru Mao 11, Hai Huang 11, Qian Chu 12,, Chengping Hu 10,
PMCID: PMC7309464  PMID: 32587786

In the published article1, the affiliation for the first author, Xingsheng Hu, is “Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences”, we would like to update it to “Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China”. We apologize for the errors and for any confusion it may have caused.

References

  • 1.Hu X, Yang D, Li Y, Li L, Wang Y, Chen P, et al. Prevalence and clinical significance of pathogenic germline BRCA1/2 mutations in Chinese non-small cell lung cancer patients. Cancer Biol Med. 2019;16:556–64. doi: 10.20892/j.issn.2095-3941.2018.0506. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cancer Biology & Medicine are provided here courtesy of Chinese Anti-Cancer Association

RESOURCES